DE1808992A1 - Pharmaceutical preparations - Google Patents
Pharmaceutical preparationsInfo
- Publication number
- DE1808992A1 DE1808992A1 DE19681808992 DE1808992A DE1808992A1 DE 1808992 A1 DE1808992 A1 DE 1808992A1 DE 19681808992 DE19681808992 DE 19681808992 DE 1808992 A DE1808992 A DE 1808992A DE 1808992 A1 DE1808992 A1 DE 1808992A1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxy
- pharmaceutical preparations
- preparations according
- phenanthroline
- quinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 21
- VLPADTBFADIFKG-UHFFFAOYSA-N phanquone Chemical compound C1=CN=C2C(=O)C(=O)C3=NC=CC=C3C2=C1 VLPADTBFADIFKG-UHFFFAOYSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 9
- WDFKMLRRRCGAKS-UHFFFAOYSA-N chloroxine Chemical compound C1=CN=C2C(O)=C(Cl)C=C(Cl)C2=C1 WDFKMLRRRCGAKS-UHFFFAOYSA-N 0.000 claims description 9
- BKMLGCPWXVBXHY-UHFFFAOYSA-N diethyl-(2-hydroxyethyl)-methylazanium Chemical compound CC[N+](C)(CC)CCO BKMLGCPWXVBXHY-UHFFFAOYSA-N 0.000 claims description 9
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229960003540 oxyquinoline Drugs 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 206010016766 flatulence Diseases 0.000 claims description 4
- 206010010774 Constipation Diseases 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 claims 1
- UKLQXHUGTKWPSR-UHFFFAOYSA-M oxyphenonium bromide Chemical compound [Br-].C=1C=CC=CC=1C(O)(C(=O)OCC[N+](C)(CC)CC)C1CCCCC1 UKLQXHUGTKWPSR-UHFFFAOYSA-M 0.000 claims 1
- 230000002048 spasmolytic effect Effects 0.000 claims 1
- 229920002472 Starch Polymers 0.000 description 21
- 239000008107 starch Substances 0.000 description 16
- 235000019698 starch Nutrition 0.000 description 16
- 239000000454 talc Substances 0.000 description 11
- 229910052623 talc Inorganic materials 0.000 description 11
- 229920000159 gelatin Polymers 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 7
- 239000008119 colloidal silica Substances 0.000 description 7
- 239000008298 dragée Substances 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
- 239000008117 stearic acid Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 241000757078 Maranta Species 0.000 description 4
- 239000005662 Paraffin oil Substances 0.000 description 4
- 244000299461 Theobroma cacao Species 0.000 description 4
- 235000009470 Theobroma cacao Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 4
- 229940109275 cyclamate Drugs 0.000 description 4
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 4
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000010215 titanium dioxide Nutrition 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- 229940100445 wheat starch Drugs 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- JMEVHYCNAPFOAB-UHFFFAOYSA-N 2-(3-hydroxy-5-sulfo-1H-indol-2-yl)-3-oxoindole-5-sulfonic acid Chemical compound Oc1c([nH]c2ccc(cc12)S(O)(=O)=O)C1=Nc2ccc(cc2C1=O)S(O)(=O)=O JMEVHYCNAPFOAB-UHFFFAOYSA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 244000151018 Maranta arundinacea Species 0.000 description 2
- QFUFIDWMZKCFNQ-UHFFFAOYSA-M [Na+].OC(=O)CC(O)(CC(O)=O)C(O)=O.CCCCCCCCCCCCOS([O-])(=O)=O Chemical compound [Na+].OC(=O)CC(O)(CC(O)=O)C(O)=O.CCCCCCCCCCCCOS([O-])(=O)=O QFUFIDWMZKCFNQ-UHFFFAOYSA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 235000012738 indigotine Nutrition 0.000 description 2
- 239000004179 indigotine Substances 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000012751 sunset yellow FCF Nutrition 0.000 description 2
- 239000004173 sunset yellow FCF Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- CGWOEOXQHIMZEQ-UHFFFAOYSA-N 3-[1-[[4-(2-phenylquinolin-3-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound OC1=NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=CC2=CC=CC=C2N=C1C1=CC=CC=C1 CGWOEOXQHIMZEQ-UHFFFAOYSA-N 0.000 description 1
- -1 4,7-phenanthroline-5,6-quinone 5,7-dichloro-8-hydroxy-quinoline Sodium lauryl sulfate Chemical compound 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000745493 Chilomastix Species 0.000 description 1
- 239000004641 Diallyl-phthalate Substances 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001502500 Trichomonadida Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- QQNAHCGZJZVKIR-UHFFFAOYSA-N acetic acid;diethyl benzene-1,2-dicarboxylate;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O.CCOC(=O)C1=CC=CC=C1C(=O)OCC QQNAHCGZJZVKIR-UHFFFAOYSA-N 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- QUDWYFHPNIMBFC-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,2-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C QUDWYFHPNIMBFC-UHFFFAOYSA-N 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- DVQAMOHJJLLZJL-UHFFFAOYSA-M diethyl-(2-hydroxyethyl)-methylazanium phenyl 2-cyclohexyl-2-hydroxyacetate bromide Chemical compound C1(=CC=CC=C1)OC(C(O)C1CCCCC1)=O.[Br-].C(C)[N+](C)(CCO)CC DVQAMOHJJLLZJL-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
CIBA AKTIENGESELLSCHAFT, BASEL (SCHWEIZ)CIBA AKTIENGESELLSCHAFT, BASEL (SWITZERLAND)
Case 6316/ECase 6316 / E
DeutschlandGermany
Pharmazeutische Präparate.Pharmaceutical preparations.
Die Erfindung betrifft neue pharmazeutische Präparate für die Behandlung und/oder Prophylaxe von akuten oder chronischen Darmerkrankungen, insbesondere dysbiotischer und/oder infektiöser Natur, wie z.B. diarrhoeischer Erkrankungen. Diese Indikationen umfassen z.B. akute Diarrhöe, chronische oder reieddi.vlerende Diarrhöe, Sommerdiarrhoe, Gastroenteritis, Enteritis, Enterocolitis, Colitis, bakterielle Dysenterie, bakterielle und parasitäre Mischinfektionen, Amoebiasis, speziell ihre chronischen Formen, Giardiasis, Trichomoniasis, durch AntibiotikaThe invention relates to new pharmaceutical preparations for the treatment and / or prophylaxis of acute or chronic intestinal diseases, especially of a dysbiotic and / or infectious nature, such as diarrhoeic Diseases. These indications include e.g. acute diarrhea, chronic or recurrent diarrhea, summer diarrhea, Gastroenteritis, enteritis, enterocolitis, colitis, bacterial dysentery, bacterial and parasitic Mixed infections, amoebiasis, especially its chronic forms, giardiasis, trichomoniasis, caused by antibiotics
»09827/U72»09827 / U72
verursachte Enteritis, wie z.B. intestinale Moniliasis. Besonders überraschend ist, dass die neuen Präparate darüberhinaus auch sehr nützlich für die Behandlung der Obstipation, des Meteorismus und der Flatulenz sind und'allgemein bei Dysbiose der Keimbesiedelung des Darmes, wie z.B. bei postoperativer Dysbiose, mit Erfolg verwendet werden können. ,caused enteritis, such as intestinal moniliasis. It is particularly surprising that the new products are beyond also very useful for the treatment of constipation, the meteorism and flatulence are und'allgemein in dysbiosis of the bacterial flora of the gut, such as in post-operative dysbiosis, can be used with success. ,
Die neuen Präparate enthalten (l) 4,7-Phenanthrolin-5,6-chinon und (2) S^-Dichlor-S-hydroxy-ehinolin zusammen mit einem pharmazeutischen Trägermaterial. Wenn erwünscht, kann den Präparaten noch ein Spasmolytikum (3) hinzugefügt werden, wie z.B. Diathyl-(2-hydroxy-äthyl)-methyl-ammoniumbromid-a-pheny1-eyelohexan-glycolat, oder eine äquivalente Verbindung, es sei denn, es handle sich um die Behandlung der Obstipation oder ähnlicher Zustände mit verminderter intestinaler Motilität. Das Gewichtsverhältnis der aktiven Substanzen in den neuen Präparaten kann variieren. Vorteilhaft enthalten sie die oben erwähnten Wirkstoffe (l) und (2) in einem Gewichtsverhältnis von ungefähr 1:2 bis ungefähr 1:40, in einer Linie von ungefähr 1:3 bis ungefähr 1:30 und gegebenenfalls den Wirkstoff (3) in einer Menge von ungefähr I/50 bis ungefähr I/3 derjenigen des Wirkstoffes (l). Bevorzugt enthalten die neuen Präparate ungefähr auf IO-3O mg 4,7-Phenanthrolin-5,6-chinon, 60-400, insbesondere IOO-3OO mg 5,7-Dichlor-8-hydroxy-chinolin und, wenn erwünscht, I-3 mg Diäthyl-(2)-hydroxy-äthyl)-methyl-ammoniumbromid-a-phenyl-cyclohexan-glycolat. The new preparations contain (l) 4,7-phenanthroline-5,6-quinone and (2) S ^ -Dichlor-S-hydroxy-ehinolin together with a pharmaceutical carrier material. If desired, an antispasmodic can be added to the preparations (3) be added, such as diethyl (2-hydroxy-ethyl) -methyl-ammonium bromide-a-pheny1-eyelohexane glycolate, or an equivalent compound, except for the treatment of constipation or similar conditions with decreased intestinal motility. The weight ratio of the active substances in the new preparations may vary. They advantageously contain the above-mentioned active ingredients (1) and (2) in a weight ratio of about 1: 2 to about 1:40, in a line from about 1: 3 to about 1:30 and optionally the active ingredient (3) in an amount from about 1/50 to about 1/3 that of the Active ingredient (l). The new preparations preferably contain about 10-3O mg of 4,7-phenanthroline-5,6-quinone, 60-400 mg, in particular 100-3OO mg 5,7-dichloro-8-hydroxy-quinoline and, if desired, 1-3 mg diethyl- (2) -hydroxy-ethyl) -methyl-ammonium bromide-a-phenyl-cyclohexane glycolate.
809827/U72809827 / U72
Besonders wertvolle Präparate enthalten, und zwar mit Vorteil in einer Einzeldosierungseinheit, auf ca. 20 mg 4,7-Phenanthrolin-5,6-chinon ca- l40 oder ca. 200 mg 5,7-Dichlor-8-hydroxychinolin und, wenn erwünscht, ca. 2 mg Diäthyl-(2-hydroxy-äthyl)-methyl-ammoniumbromid-a-phenyl-cyclohexanglycolat. Die tägliche Dosis hängt von den individuellen Erfordernissen des einzelnen Patienten ab und kann leicht vom behandelnden Arzt festgestellt werden. Vorteilhaft entspricht sie ungefähr einer Menge von etwa 60 mg 4,7-Phenanthrolin-5,6-chinon, 420 mg oder 600 mg 5,7-Dichlor-8-hydroxychinolin und, wenn erwünscht, 6 mg Diäthyl-(2-hydroxy-äthyl)-methyl-ammoniumbromida-phenyl-cyclohexan-glycolat. Diese tägliche Dosis kann z.B. in 2 oder 3 einzelne Dosen aufgeteilt werden. In schweren Fällen kann die tägliche Dosis auch verdoppelt werden. Kinder erhalten natürlich kleinere Dosen, z.B. I/3 oder 2/3 der Normaldosis.Particularly valuable preparations contain, with advantage in a single dosage unit, to approx. 20 mg 4,7-phenanthroline-5,6-quinone approx. 140 or approx. 200 mg of 5,7-dichloro-8-hydroxyquinoline and, if desired, approx. 2 mg of diethyl (2-hydroxyethyl) methyl ammonium bromide-a-phenyl-cyclohexane glycolate. The daily dose depends on the individual requirement of the individual patient and can easily be determined by the attending physician. Advantageously, it corresponds about an amount of about 60 mg 4,7-phenanthroline-5,6-quinone, 420 mg or 600 mg 5,7-dichloro-8-hydroxyquinoline and, if desired, 6 mg diethyl (2-hydroxy-ethyl) -methyl-ammonium bromide-phenyl-cyclohexane-glycolate. This daily dose can e.g. be divided into 2 or 3 individual doses. In serious In some cases, the daily dose can be doubled. Children of course receive smaller doses, e.g. I / 3 or 2/3 of the normal dose.
Die neuen Präparate besitzen ein Aktivitätsspektrum, das von der reinen Parasitose bis zu spezifischen bakteriellen Erkrankungen des Darmes reicht, und umfasst daher auch bakterielle und parasitäre Mischinfektionen ebensogut, wie Erkrankungen, die durch ein gestörtes Gleichgewicht der bakteriellen Eubiose des Darmes verursacht werden. Speziell in Erkrankungen unspezifischer oder unspezifizierbarer Natur, die im allgemeinen teilweise auf einer Veränderung der physiologischen Flora beruhen, zeigen dieThe new preparations have a spectrum of activity ranging from pure parasitosis to specific ones bacterial diseases of the intestine, and therefore also includes bacterial and parasitic mixed infections just as well as diseases caused by a disturbed balance of bacterial eubiosis of the intestine. Especially in diseases of an unspecific or unspecific nature, which are generally partly due to a Change in the physiological flora are based, show the
neuen Präparate sehr gute Wirkung. Im speziellen sind dienew preparations very effective. In particular they are
909827/U72909827 / U72
neuen Präparate antibakteriell aktiv gegen Coccen, gewisse pathogene Enterobakterien, wie Dysenteriebazillen, und gegen pathogene Hefen. Sie besitzen ferner antiparasitäre Eigenschaften gegen Amoeben, Giardia lamblia, Trichomonaden, Chilomastix. Sie sind daher nützlich für die Behandlung entsprechender intestinaler Erkrankungen. Auf Grund eines synergistischen Effektes der verschiedenen antibakteriellen Wirkstoffe der Kombination, z.B. in bezug auf ihre antibakterielle Aktivität gegen Sh. sonnei, S. aureus,und gegen C. albicans und in bezug auf ein verändertes Spektrum der Aktivität gegen die intestinalen Bakterien^und Protozoenflora, besitzen die neuen Präparate eine besonders wertvolle chemotherapeutische Wirkung.new preparations antibacterially active against cocci, certain pathogenic enterobacteria such as dysentery bacilli and against pathogenic yeasts. They also have anti-parasitic Properties against amoeba, Giardia lamblia, trichomonads, Chilomastix. They are therefore useful for the treatment of related intestinal diseases. Because of a synergistic effect of the different antibacterial agents of the combination, e.g. with regard to their antibacterial activity against Sh. sonnei, S. aureus, and against C. albicans and in relation to an altered spectrum of activity against intestinal bacteria ^ and protozoal flora, the new preparations have a particularly valuable chemotherapeutic effect.
Die neuen Präparate erhält man nach konventionellen Methoden der Arzneimittelherstellung. Dabei kann man Hilfsstoffe verwenden, die mit den Wirkstoffen nicht reagieren, wie z.B. Gelatine, Laktose, Stärken, Stearinsäure, Magnesiumstearat, Stearylalkohol, Talkum, pflanzliche OeIe, Benzylalkohole, Gummi, Propylenglykole, Polyalkylen oder andere bekannte Arzneimittelträger. Die Präparate liegen vorzugsweise in fester Form vor, z.B. in Form von Kapseln*, Tabletten oder Dragees. Sie können aber auch in flüssiger Form, z.B. in Form eines Sirups, vorliegen. Wenn erwünscht, so können sie noch andere Hilfsstoffe, wie Konservierungs-The new preparations are obtained using conventional drug production methods. You can use auxiliaries use that do not react with the active ingredients, such as gelatin, lactose, starches, stearic acid, magnesium stearate, Stearyl alcohol, talc, vegetable oils, benzyl alcohol, Gum, propylene glycols, polyalkylene, or other known excipients. The preparations preferably lie in solid form, e.g. in the form of capsules *, tablets or coated tablets. However, they can also be in liquid form, e.g. in the form of a syrup. If desired, so can you add other additives, such as preservatives
909827/U72909827 / U72
mittel, Färb- oder Geschmacksstoffe, enthalten. Sie können auch noch weitere therapeutisch nützliche Verbindungen aufweisen. contain agents, colorings or flavorings. You can also have other therapeutically useful compounds.
Die neuen Präparate sind nicht nur in der Humanmedizin, sondern auch in der Veterinärmedizin, für die Behandlung ähnlicher Krankheiten wertvoll, wie z.B. bei Pferden oder Katzen.The new preparations are not only used in human medicine, but also in veterinary medicine, for treatment similar diseases, such as horses or cats.
Die Erfindung betrifft auch die Herstellung der neuen Präparate, die dadurch gekennzeichnet ist, dass man in an sich bekannter Weise die Wirkstoffe (l), (2) und gegebenenfalls (3) mit Trägerstoffen in üblicher Weise zu den gewünschten Anwendungsformen verarbeitet.The invention also relates to the manufacture of the new preparations, which is characterized in that in a known manner the active ingredients (l), (2) and optionally (3) processed with carriers in the customary manner to give the desired application forms.
Die Erfindung wird in den nachfolgenden Beispielen beschrieben, ohne sie jedoch einzuschränken. Die Temperaturen sind in Celsiusgraden angegeben.The invention is described in the following examples without, however, restricting it. The temperatures are given in degrees Celsius.
909827/U72909827 / U72
Auf folgende Weise können Dragees hergestellt werden:Dragees can be made in the following ways:
1 Drageekern enthält: 4,7-Phenanthroliii-5,6-chinon 5,7-Dichlor-8-hydroxy-chinolin 1 tablet core contains: 4,7-phenanthroliii-5,6-quinone 5,7-dichloro-8-hydroxy-quinoline
Diäthyl-(2-hydroxy-äthyl)-methyl-ammonium- " bromid-a-phenyl-cyclohexan-glycolatDiethyl- (2-hydroxy-ethyl) -methyl-ammonium- " bromide-a-phenyl-cyclohexane-glycolate
Natriumdodecylsulfat Zitronensäure Weizenstärke GelatineSodium dodecyl sulfate Citric acid wheat starch gelatin
Kolloidale Kieselsäure mit hydrolysierter StärkeColloidal silica with hydrolyzed starch
Marantastärke Stearinsäure TalkumMaranta starch stearic acid talc
Celluloseacetat-phthalat Diäthylphthalat TalkumCellulose acetate phthalate diethyl phthalate talc
Nicht-quellende Stärke Titandioxyd Gummi arabicum GelatineNon-swelling starch titanium dioxide gum arabic gelatin
909827/U72909827 / U72
Zucker 164,19 mg Sugar 164.19 mg
Orangegelb S SpurenOrange-yellow S traces
Indigotin. SpurenIndigotine. traces
240,0 mg240.0 mg
Herstellung der Drage'ekerne: ' Production of the Drage'ekerne: '
Von einer feinen Mischung der aktiven Substanzen und einer wässrigen Lösung Von Natriumdodecylsulfat und Zitronensäure bereitet man eine feuchte Mischung", Diese Mischung wird mit einer Gelatine-Stärke-Paste unter Beifügung von kolloidaler Kieselsäure zu einer plastischen,granulierfähigen Masse geknetet. Diese Masse wird granuliert, vollständig getrocknet, mit Marantastärke,kolloidaler Kieselsäure, Talkum und Stearinsäure vermischt und in üblicher Weise in einer Tablettenmaschine zu Drageekernen gepresst, welche leicht zerfallen.A f a mixture of the active substances and an aqueous solution of sodium dodecyl sulfate and citric acid prepares to a wet mix ", this mixture is kneaded with a gelatin starch paste with the addition of colloidal silica to a plastic, granulierfähigen mass. This mass is granulated , completely dried, mixed with maranta starch, colloidal silica, talc and stearic acid and pressed in the usual way in a tablet machine to form tablet cores, which disintegrate easily.
In einer Dragierpfanne werden die Drage'ekerne lagenweise mit einer Suspension, bestehend aus Zelluloseacetat-phthalat, Diäthylphthalat, Talkum und organischen Lösungsmitteln so lange überzogen, bis sie in einem Test mit künstlichem Magensaft während mindestens 2 Stunden resistent sind, aber in einem künstlichen Darmsaft innerhalb ungefähr 20 Minuten vollständig zerfallen.The dragee cores are layered in a coating pan with a suspension consisting of cellulose acetate phthalate, diethyl phthalate, talc and organic solvents so long coated until they are resistant in a test with artificial gastric juice for at least 2 hours, but in an artificial intestinal juice completely disintegrate within about 20 minutes.
909827/U72909827 / U72
Die magenresistent überzogenen Kerne werden lagenweise mit einer wässrigen Suspension, enthaltend Zucker, nicht-quellende Stärke, Gummi arabicum, Gelatine und Titandioxyd überzogen, bis die Lackschicht vollständig bedeckt ist. Dann folgt ein Ueberzug mit einer gefärbten Zuckerlösung, bis das Gewicht $kO mg beträgt. Die rohen Dragees werden gut getrocknet und dann in einer Poliertrommel poliert.The stomach-resistant coated cores are coated in layers with an aqueous suspension containing sugar, non-swelling starch, gum arabic, gelatine and titanium dioxide until the lacquer layer is completely covered. Then follows a coating with a colored sugar solution until the weight is $ kO mg. The raw coated tablets are dried well and then polished in a polishing drum.
Dragees, bei welchen die Drage"ekerne die nach-,
folgende Zusammensetzung aufweisen, können analog Beispiel 1 hergestellt werden:
4,7-Phenanthrolin-5,6-chinon
5,7-Dichlor-8-hydroxy-chinolin
Natriumlaurylsulfat
Weizenstärke
GelatineDragees in which the coated cores have the following composition can be produced analogously to Example 1:
4,7-phenanthroline-5,6-quinone
5,7-dichloro-8-hydroxy-quinoline
Sodium lauryl sulfate
Wheat starch
gelatin
Kolloidale Kieselsäure mit hydrolysierter StärkeColloidal silica with hydrolyzed starch
Marantastärke Stearinsäure TalkumMaranta starch stearic acid talc
90-98 27/U7290-98 27 / U72
Eine oral verabreichbare Suspension kann wie folgt hergestellt werden:An orally administrable suspension can be prepared as follows:
4,7-Phenanthrolin-5,6-chinon . 0,8 g4,7-phenanthroline-5,6-quinone. 0.8 g
5,7-Dichlor-S-hydroxy-chinolin 8,0 g5,7-dichloro-S-hydroxy-quinoline 8.0 g
Cacaopulver 4,6 gCocoa powder 4.6 g
Cyclamat 4,6 gCyclamate 4.6 g
Glycerinmonostearat 0,5 gGlycerol monostearate 0.5 g
Aroma 0,08gFlavor 0.08g
Paraffinöl ad 100 mlParaffin oil ad 100 ml
Paraffinöl wird erwärmt, Glycerinmonostearat darin gelöst und in der erhaltenen Lösung 5,7-Dichlor-8-hydroxy-chinolin, Cyclamat und Cacaopulver homogen suspendiert.Paraffin oil is warmed up and glycerol monostearate is dissolved in it and in the resulting solution 5,7-dichloro-8-hydroxy-quinoline, Cyclamate and cocoa powder suspended homogeneously.
Darauf wird 4,7-Phenanthrolin-5,6-chinon in die Suspension bei Zimmertemperatur eingearbeitet, das Aroma zugesetzt und das Präparat mit einem geeigneten Homogenisator homogenisiert und1 abgefüllt in Tropffläschchen.It, 4,7-phenanthroline-5,6-quinone is incorporated in the suspension at room temperature, added to the flavor and homogenized, the preparation with a suitable homogenizer and filled into 1 dropper bottle.
909827/ U72909827 / U72
- ίο -- ίο -
Auf folgende Weise können Dragees hergestellt werden:Dragees can be made in the following ways:
1 Drageekern enthält: 4,7-Phenanthrdlin-5,6-chinon 5,7-Dichlor-8-hydroxy-chinolin 1 tablet core contains: 4,7-phenanthrdline-5,6-quinone 5,7-dichloro-8-hydroxy-quinoline
Diäthyl-(2-hydroxy-äthyl) -methyl -ammonium- ·· bromid-a-phenyl-cyclohexan-glycolat Diethyl (2-hydroxy-ethyl) -methylammonium- ·· bromide-a-phenyl-cyclohexane-glycolate
Natriumdodecylsulfat Zitronensäure Weizenstärke > GelatineSodium dodecyl sulfate Citric Acid Wheat Starch> Gelatin
Kolloidale Kieselsäure mit hydrolysierter ' StärkeColloidal silica with hydrolyzed 'starch
Marantastärke StearinsäureMaranta starch stearic acid
Talkumtalc
240,0 mg Drage"e-Ueberzug: 240.0 mg coated tablet:
Celluloseaoetat-phthalat 12,0 mgCellulose acetate phthalate 12.0 mg
Diäthylphthalat 3,0 mgDiethyl phthalate 3.0 mg
Talkum 55,5 mgTalc 55.5 mg
Nicht-quellende Stärke 2,55 mgNon-swelling starch 2.55 mg
Titandioxyd 0,89 mgTitanium dioxide 0.89 mg
Gummi arabicum 1,70 mgGum arabic 1.70 mg
Gelatine . 0,17 mgGelatin. 0.17 mg
9 0 9827/ U729 0 9827 / U72
Zucker l64,19 mgSugar 164.19 mg
Orangegelb S SpurenOrange-yellow S traces
Indigotin SpurenIndigotine traces
240,0 mg240.0 mg
Von einer feinen Mischung der aktiven Substanzen und einer wässrigen Lösung von Natriumdodecylsulfat und Zitronensäure bereitet man eine feuchte Mischung", Diese Mischung wird mit einer Gelatine-Stärke-Paste unter Beifügung von kolloidaler Kieselsäure zu einer plastischen,granulierfähigen Masse gekretet. Diese Masse wird granuliert, vollständig getrocknet, mit Marantastärke,kolloidaler Kieselsäure, Talkum und Stearinsäure vermischt und in üblicher Weise in einer Tablettenmaschine zu Drageekernen gepresst, welche leicht zerfallen.From a fine mixture of the active substances and an aqueous solution of sodium dodecyl sulfate and citric acid one prepares a damp mixture ", this mixture is made with a gelatin-starch paste with the addition of colloidal Silicic acid secreted into a plastic, granulable mass. This mass is granulated, completely dried, mixed with maranta starch, colloidal silica, talc and stearic acid and in the usual way in one Tablet machine pressed into tablet cores, which disintegrate easily.
In einer Dragierpfanne werden die Drage'ekerne lagenweise mit einer Suspension, bestehend aus Zelluloseacetat-phthalat, Diallylphthalat, Talkum und organischen Lösungsmitteln so lange überzogen, bis sie in einem Test mit künstlichem Magensaft während mindestens 2 Stunden resistent sind, aber in. einem künstlichen Darmsaft innerhalb ungefähr 20 Minuten vollständig zerfallen.The dragee cores are layered in a coating pan with a suspension consisting of cellulose acetate phthalate, Diallyl phthalate, talc and organic solvents so long coated until they are resistant in a test with artificial gastric juice for at least 2 hours, but in. an artificial intestinal juice completely disintegrate within about 20 minutes.
909827/U72909827 / U72
Aeusserer Ueberzug: Outer coating :
Die magenresistent überzogenen Kerne werden lagenweise mit einer wässrigen Suspension, enthaltend Zucker, nicht-quellende Stärke, Gummi arabicum, Gelatine und Titandioxyd * überzogen, bis die Lackschicht vollständig bedeckt ist'. Dann folgt ein Ueberzug mit einer gefärbten Zuckerlösung, bis das Gewicht 480 mg beträgt. Die rohen Dragees werden gut getrocknet und dann in einer Poliertrommel poliert.The stomach-resistant coated kernels are layered with an aqueous suspension containing sugar, non-swelling Starch, gum arabic, gelatine and titanium dioxide * coated until the lacquer layer is completely covered '. Then follows a coating with a colored sugar solution until the weight is 480 mg. The raw dragees are made well dried and then polished in a buffing drum.
Dragees, bei welchen die Drageekerne die nachfolgende Zusammensetzung aufweisen, können analog Beispiel 1
hergestellt werden:
4,7-Phenanthrolin-5,6-chinon
5,T-Dichlor-S-hydroxy-chinolin
Natriumlaury1sulfat
Weizenstärke
GelatineCoated tablets in which the coated tablet cores have the following composition can be produced analogously to Example 1:
4,7-phenanthroline-5,6-quinone
5, T-dichloro-S-hydroxy-quinoline
Sodium lauryl sulfate
Wheat starch
gelatin
Kolloidale Kieselsäure mit hydrolysierter StärkeColloidal silica with hydrolyzed starch
Marantastärke Stearinsäure TalkumMaranta starch stearic acid talc
200,0 mg 90-9827/U72 200.0 mg 90-9827 / U72
Eine oral verabreichbare Suspension kann wie folgt hergestellt werden:An orally administrable suspension can be prepared as follows:
4,7-Phenanthrolin-5,6-chinon 0,8 g4,7-phenanthroline-5,6-quinone 0.8 g
5,7-Diehlor-8-hydroxy-chinolin 5/6 g5,7-Diehlor-8-hydroxy-quinoline 5/6 g
Cacaopulver 4,6 gCocoa powder 4.6 g
Cyclamat 4,6 gCyclamate 4.6 g
Glycerinmonostearat 0,5 gGlycerol monostearate 0.5 g
.Aroma 0,08g.Aroma 0.08g
Paraffinöl ad 100 mlParaffin oil ad 100 ml
Paraffinöl wird erwärmt, Glycerinmonostearat darin gelöst und in der erhaltenen Lösung S^-Dichlor-S-hydroxy-chinolin, Cyclamat und Cacaopulver homogen suspendiert.Paraffin oil is warmed up and glycerol monostearate is dissolved in it and in the solution obtained S ^ -Dichlor-S-hydroxy-quinoline, Cyclamate and cocoa powder suspended homogeneously.
Darauf wird 4,7-Phenanthrolin-5,6-chinon in dieThen 4,7-phenanthroline-5,6-quinone is added to the
Suspension bei Zimmertemperatur eingearbeitet, das Aroma zugesetzt und das Präparat mit einem geeigneten Homogenisa'-tor homogenisiert und abgefüllt in Tropffläschchen.Incorporated suspension at room temperature, added the aroma and the preparation with a suitable homogenizer homogenized and filled into dropper bottles.
909827/U72909827 / U72
Claims (20)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1652867 | 1967-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1808992A1 true DE1808992A1 (en) | 1969-07-03 |
Family
ID=4418144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19681808992 Pending DE1808992A1 (en) | 1967-11-24 | 1968-11-15 | Pharmaceutical preparations |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE724372A (en) |
| DE (1) | DE1808992A1 (en) |
| FR (1) | FR8098M (en) |
| GB (1) | GB1200999A (en) |
| IE (1) | IE32498B1 (en) |
| IL (1) | IL31086A (en) |
| NL (1) | NL6816740A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006117660A2 (en) * | 2005-05-04 | 2006-11-09 | Clio Pharmaceutical Corporation | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins |
-
1968
- 1968-11-15 DE DE19681808992 patent/DE1808992A1/en active Pending
- 1968-11-18 IL IL31086A patent/IL31086A/en unknown
- 1968-11-19 FR FR174320A patent/FR8098M/fr not_active Expired
- 1968-11-20 IE IE1401/68A patent/IE32498B1/en unknown
- 1968-11-22 BE BE724372D patent/BE724372A/xx unknown
- 1968-11-22 NL NL6816740A patent/NL6816740A/xx unknown
- 1968-11-25 GB GB55743/68A patent/GB1200999A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IE32498L (en) | 1969-05-24 |
| IL31086A0 (en) | 1969-01-29 |
| GB1200999A (en) | 1970-08-05 |
| NL6816740A (en) | 1969-05-28 |
| IE32498B1 (en) | 1973-08-22 |
| IL31086A (en) | 1972-04-27 |
| BE724372A (en) | 1969-05-22 |
| FR8098M (en) | 1970-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2813480C2 (en) | Multi-unit dose type depot drug preparation | |
| DE1106454B (en) | Coating agents for drugs | |
| DE2206570A1 (en) | Remedies for treating liver affections | |
| DE2251250A1 (en) | PROCESS FOR MANUFACTURING HIGH DOSE ANTIBIOTICA TABLETS | |
| CH638681A5 (en) | Pharmaceutical containing Echinacea and lactic acid derivatives and process for its preparation | |
| DE2259646A1 (en) | HIGH DOSE TABLETS OF CEPHALOSPORIN DERIVATIVES AND THE METHOD FOR THEIR MANUFACTURING | |
| DE3034975C2 (en) | Drug combination used to treat infectious respiratory diseases | |
| DE1808992A1 (en) | Pharmaceutical preparations | |
| DE2823655A1 (en) | MEDICINES FOR TREATING BACTERIAL AFFECTS | |
| DE2028880A1 (en) | N-phenyl carbamoyl derivs of 3-beta-phenyl isopropyl-synononimines - - as psycho and cns | |
| DE1043587B (en) | Process for making an appetite suppressant | |
| DE3315607A1 (en) | USE OF ALBENDAZOL IN ORAL ADMINISTRATION FOR CONTROLLING ECHINOCOCCOSIS OF MAN AND MEDICINAL PRODUCTS | |
| DE3108068A1 (en) | N-Methanesulphonic acids and alkali metal N-methanesulphonates of sisomicin, gentamicin and their derivatives, process for their preparation, pharmaceutical compositions containing these compounds, and their use as antibiotics | |
| DE2521922A1 (en) | PHARMACEUTICAL PRODUCTS | |
| DE2342214C3 (en) | Remedies | |
| DE2157201A1 (en) | Oral application forms of raubasine-contg polyethylene - glycol and an organic acid | |
| DE1229084B (en) | Process for the preparation of tetracycline cyclohexyl sulfamate | |
| DE2256538C2 (en) | Probenecid salt of the pivaloyloxymethyl ester of D - (-) - α-aminobenzylpenicillin, its preparation and pharmaceutical compositions containing the same | |
| DE3322337A1 (en) | NEW PHARMACEUTICAL PREPARATIONS WITH ANTITUARY EFFECT | |
| DE1967186C3 (en) | Medicinal products containing 4,4-diarylpiperidines | |
| DE2131193A1 (en) | Drug preparation | |
| DE2140464A1 (en) | Erythromycin urchins, processes for their preparation and medicines containing these compounds | |
| DE2501649A1 (en) | PAPAVERINE THIOPHEN CARBONIC ACID SALT, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| EP0192098A2 (en) | Use of 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin for the preparation of a medicament for the treatment of Parkinson's disease, or of parkinsonism | |
| DE2142385C3 (en) | 1-Adamanty1-4- (3 "-nitrophenyl) -I ^ .S.e-tetrahydropyrimidin ^ -one, process for its preparation and medicaments containing this compound |